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Objective:
 
 To determine if patients who were noncom-
pliant with prescribed medications for chronic obstruc-
tive pulmonary disease (COPD) had higher rates of hos-
pitalization.
 
Methods:
 
 A retrospective case-control study was per-
formed in a tertiary-care university-affiliated Veterans
Administration Health Care System setting. Subjects in-
cluded 93 patients hospitalized for exacerbation of
COPD and 93 controls with a diagnosis of COPD who
did not require hospitalization. Utilizing pharmacy pre-
scription fill records, medication noncompliance rates
of patients who required hospitalization for exacerba-
tion of COPD were compared with patients who did
not require such hospitalization.
 
Results:
 
 The mean noncompliance ratio for the hospi-
talized patients was lower than the ratio for the con-
trols (0.19 vs. 0.20) although the difference was not sta-
 
tistically significant (
 
P
 
 
 

 
 .95). There was no statistically
significant difference between the demographics of the
two groups. However, the patients who were hospital-
ized had a significantly greater number of COPD and
nonCOPD medications (
 
P
 
 
 

 
 .0001, 
 
P
 
 
 

 
 .0001) pre-
scribed. They also had significantly more nonCOPD ad-
missions and lengths of stay (
 
P
 
 
 

 
 .02, 
 
P
 
 
 

 
 .01).
 
Conclusion:
 
 At the levels of medication noncompliance
observed in this population, there was no difference in
rates of hospitalization. Hospitalization could be attrib-
uted to other causes such as severity of illness and exist-
ence of other comorbid conditions. The effects of environ-
mental pollution and cigarette smoking were not studied.
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pitalization, noncompliance; risk factors.
 
Introduction
 
Chronic obstructive pulmonary disease (COPD) is
a chronic disabling condition, afflicting over 16
million individuals in the United States. Its preva-
lence is exceeded only by hypertension and heart
disease [1]. In 1990, COPD was the underlying
cause in 4.0% of all deaths, making it the fifth
leading cause of death [2]. Health resource utiliza-
tion is high among patients with COPD; com-
pared to the general population, COPD patients
have twice the number of short hospital stays [3].
Since inpatient hospital costs are a substantial com-
ponent of total healthcare costs, even a small de-
crease in COPD hospitalizations should result in
sizable savings. This becomes increasingly signifi-
cant in the face of growing budgetary constraints
and the fact that COPD results in a large number
of hospital admissions annually.
Despite advances in diagnosis and treatment,
patients often fail to obtain optimal outcomes be-
cause they do not adhere to treatment instructions
[3]. The direct and indirect costs of medication
noncompliance are estimated to be as high as
$100 billion, with hospital costs accounting for
about $25 billion of this total amount [4]. It has
been suggested that improving compliance with
prescription medications may possibly reduce an-
nual healthcare expenditures by over $80 billion
[4]. Moreover, numerous studies imply that there
is a positive correlation between medication non-
compliance and repeated readmissions to the hos-
pital for chronic conditions. Vinson et al. [5]
found that up to 15% of preventable readmissions
of elderly patients with congestive heart failure
were due to medication noncompliance. Maronde
et al. [6], in a study designed to observe the associ-
ation between underutilization of antihypertensive
drugs and associated hospitalization, found a sta-
tistically significant correlation. Patients who re-
quired readmission to the hospital for hyperten-
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sion-related complications had obtained fewer
prescription refills and had more days without
medications than those who did not require read-
mission. A study of psychiatric patients to identify
modifiable risk factors for rehospitalization showed
that medication noncompliance was one of the
significant factors that led to increased rehospital-
ization [7]. Soumerai et al. [8] studied the effects
of Medicaid drug-payment limits and found that
placing such limits resulted in a decrease in medi-
cation use and a statistically significant increase in
admissions to nursing homes. Swanson et al. [9]
studied the economic impact of noncompliance in
kidney transplant recipients and found a statisti-
cally significant difference in the mean number of
readmissions in the noncompliant group.
Conversely, a study designed to assess the level
of compliance with digoxin therapy by measuring
serum digoxin concentrations suggested that devi-
ation from the prescribed drug regimen may, in
fact, have protected patients from potential toxic-
ity when physicians failed to lower the dose in
older patients with impaired renal function [10]. A
recent study examining whether increasing access
to primary care by assigning patients to a health-
care team improved outcomes among chronically
ill veterans showed that such interventions actu-
ally increased hospital admissions. Although the
study did not specifically measure medication com-
pliance, the interventions, which included tele-
phone follow-up calls by the primary care nurse to
assess potential difficulties with medications and
medical regimens, were designed to improve com-
pliance [11].
While many studies have attempted to measure
compliance and the attendant reasons for non-
compliance, only a few have been directed specifi-
cally to COPD patients [3]. A study in Jerusalem
found that of the 2.9% of hospital medical admis-
sions due to noncompliance with drug therapy,
about one-sixth were for exacerbation of COPD
[12]. Hallas et al. [13] evaluated admissions to a
department of respiratory medicine and found
that one-half of the admissions due to dose-related
therapeutic failure were the result of noncompli-
ance. Powell [14] assessed compliance in a small
sample of COPD patients with caregivers in nurs-
ing homes and found that the mean compliance
with medications was 73.4%.
Coupled with smoking cessation and oxygen
therapy, drug therapy is one of the mainstays of
treatment of COPD. This study was carried out to
determine if there was any relationship between
noncompliance with drug therapy for COPD and
increased hospitalization. Identification of any
positive association would point to the need to im-
plement further measures to enhance patient com-
pliance.
 
Methods
 
A retrospective case-control study was performed.
The null hypothesis was that COPD patients more
compliant with their COPD medications would be
hospitalized at similar rates as noncompliant
COPD patients. The sample study population con-
sisted of all patients (
 
n
 
 
 

 
 1060) who used the Vet-
eran Lakeside Medical Center during the study pe-
riod (between July 1, 1995 and June 30, 1996),
and who had a diagnosis of COPD with the fol-
lowing International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) codes:
491.0, 491.1, 491.20, 491.21, 491.8, 491.9, 492.0,
492.8, and 496 [15]. The cases were all eligible pa-
tients admitted to the hospital during the study pe-
riod with a primary diagnosis of COPD. The con-
trol group consisted of an equal number of
randomly-selected COPD diagnosed patients from
the study population who did not have a hospital
admission with a primary diagnosis of COPD dur-
ing the study period. The following patients were
excluded from the study:
1. Patients who did not receive maintenance med-
ications for COPD for at least 4 months during
the study period as determined from inpatient
and outpatient pharmacy records.
2. Patients who were nursing home residents.
Such patients receive their prescriptions from
an outside contractor and their records were
not available in the hospital database.
3. Patients who were started on COPD medica-
tions only after admission to the hospital.
These patients were excluded since their admis-
sion could not be attributed to compliance.
The method described by Steiner et al. [16] was
used to measure the degree of noncompliance,
based on the assumption that patients cannot be
compliant if they have not obtained a sufficient
supply of medication. This method matched the
number of doses dispensed to the patient against
the expected usage prescribed by the treating phy-
sician to indirectly measure compliance. While not
perfect, this method does allow for an estimation
of patient medication-taking behavior that can be
readily determined by reviewing accessible prescrip-
tion transaction databases. In summary, Steiner’s
method calculates:
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(1)
(2)
 
*(365 days in this study)
 
Diagnosis codes, demographics, and prescription
fill data were retrieved from the medical center’s
integrated computer database. Pharmacy prescrip-
tion fill records of medications for COPD were
obtained directly from computerized records and
used to calculate the number of days patients were
without medications. It is assumed that the reli-
ability of both hospitalization and prescription fill
information of VA patients may be better than the
general population, since all patients are identified
by their Social Security number. All prescriptions
are filled in a central location and entered into an
integrated database. Information from all hospi-
tals in the system nationwide can be accessed from
any site. It should be noted that patients may also
have a financial disincentive to fill their prescrip-
tions at outside pharmacies since medications are
dispensed free of charge at the VA pharmacy ex-
cept for a monthly $2 copay for prescriptions for
nonservice connected disabilities. Steiner et al.
[16] found that 98.5% of hypertensive patients
seen at a VA medical center filled their prescrip-
tions at the VA pharmacy. The data are entered
into the computer by pharmacists and verified
when prescriptions are filled. Prescription labels
can be generated only if the data are first entered
into the computer database. Information entered
includes the name of the drug, dose, quantity is-
sued, and the date the prescription is released to
the patient. Chronic medications are usually filled
with a 90-day supply in accordance with Veterans
Affairs policy and are refillable up to 3 months if
authorized by the prescriber. Refills can be or-
dered through the mail or by telephone. Refills are
given only if requested by the patient. Between
55% to 60% of the prescriptions are dispensed by
mail. Any prescriptions returned as nondeliverable
in the mail are flagged in the computer as not dis-
pensed. If a patient has a prescription filled at any
other VA facility in the nation, the pharmacist en-
tering the prescription information in the patient’s
profile is alerted by a message. Prescription infor-
mation from all VA hospitals in the country is
routinely available and was used for this study.
days of medication coverage
number of drug units dispensed
number of drug units prescribed daily
-----------------------------------------------------------------------------------------
=
noncompliance ratio
days without medication
days of medication coverage for a specified time period*
----------------------------------------------------------------------------------------------------------------------------------------
=
 
Detailed prescription information, including
quantities, doses, directions for use, and fill dates,
were collected for the study period and the 3 months
immediately preceding the period. The 3-month
buffer was included to take into account any accu-
mulation of medications prior to the study period.
For each patient, the days that the patient was
without medications was calculated in the follow-
ing manner: The total quantity dispensed (numer-
ator) was divided by the daily dose (denominator)
to calculate the number of days supply. In the case
of metered-dose inhalers, the number of puffs con-
tained in each canister was divided by the pre-
scribed daily dose to calculate the days supply.
“PRN” metered-dose inhalers were few and were
not included in the calculations since there was no
way of assessing compliance. If a patient was late
in getting a prescription refilled, the number of
days he or she was late was recorded as days with-
out drug. If a patient received early refills, the ex-
tra supply was accrued and applied to days with-
out drug due to future late refills. Once this
accumulated amount was exhausted any period
until the next refill was recorded as days without
drug. If a patient was hospitalized during the
study period, the medication supplied during the
inpatient stay was taken into account when calcu-
lating the number of days supply of medications
the patient had at home. If a patient’s daily dosage
was changed, the number of days supply was re-
calculated for all the medications the patient had
on hand at that time. The total number of days
without drug and the total number of days each
drug was prescribed were calculated. The ratio of
the number of days without drug to the number of
days the drug was prescribed was computed. This
ratio is the degree of noncompliance.
The Veteran Lakeside Medical Center has a re-
stricted formulary with the following common
classes of drugs used to treat COPD.
• Anticholinergics—ipratropium inhaler;
• Beta agonists—albuterol and metaproterenol
inhalers;
• Inhaled steroids—beclomethasone and flunisol-
ide inhalers;
• Xanthines—oral theophylline.
Since a prescriber may switch drugs within a class,
each therapeutic class of drugs was treated as a
single drug when calculating the days without
drug. The average of the noncompliance ratio of
each class of drugs was taken as the mean non-
compliance ratio.
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There were a total of 170 admissions for COPD
during the study period. The total number of pa-
tients was 119, with 24 patients having multiple
admissions ranging from two to seven. Twenty-six
patients were excluded from the study because
they did not meet the criteria: twenty patients did
not start COPD medications until they were ad-
mitted to the hospital, five patients did not have
any maintenance COPD medications prescribed
for at least a 4-month period, and prescription fill
information was not available for one patient who
was confined to a nursing home and received med-
ications from a private contractor. The total num-
ber of eligible patients was 93. These were desig-
nated as the cases. An equal number of patients
was selected at random from the study population
and designated as the controls. Chi-square or
Fisher’s exact tests were performed as appropriate
to test for the differences in gender, ethnicity, and
marital status between the cases and controls. The
Wilcoxon Rank Sum and Kruskal–Wallis tests
were used to examine the differences in age be-
tween the groups.
Treating the degree of noncompliance as a con-
tinuous variable, the nonparametric Wilcoxon
Rank Sum and Kruskal–Wallis tests were used to
compare the hospitalized and control groups. Ad-
ditionally, the distribution of cases and controls at
the following noncompliance levels, 
 

 
0.2, 0.2 to
 

 
0.4 and 
 

 
0.4, were compared using the chi-
square test of Fisher’s exact test as appropriate, to
see if noncompliance at those levels affected the
number of hospitalizations.
 
Results
 
No statistically significant differences were ob-
served in the demographic characteristics of the
two groups (Table 1). There was a significant dif-
ference (
 
P
 
 
 

 
 .0001, two-tailed) in the mean num-
ber of COPD medications utilized by the cases
group (3.28; SE 
 

 
 0.06) and the controls group
(2.66; SE 
 

 
 0.09). The median was 3 for both
groups. There was also a significant difference (
 
P
 
 
 

 
.0001) in the mean number of nonCOPD medica-
tions the two groups utilized for other chronic
conditions. The mean for the cases was 12.22 (SE 
 

 
0.64) and the mean for the controls 8.66 (SE 
 

 
0.51). The medians were 12 and 8, respectively.
There was a significant difference between the
nonCOPD hospital admissions (
 
P
 
 
 

 
 .02) and length
of stay (
 
P
 
 
 

 
 .003) between the two groups. The
cases had a mean nonCOPD admission rate of
0.99 (SE 
 

 
 0.16) with a mean length of stay (LOS)
of 9.53 days. The controls had a mean nonCOPD
admission rate of 0.66 (SE 
 

 
 0.15) with a LOS of
3.68 (SE 
 

 
 0.99).
Contrary to expectations, it was found that the
patients who required admission to the hospital for
exacerbation of COPD were more compliant in
taking their medications (noncompliance ratio of
 
Table 1
 
Comparisons between patients hospitalized for exacerbation of COPD (cases) and not hospitalized COPD 
patients (controls)
 
Variable Cases (
 
n
 
 
 

 
 93) Controls (
 
n
 
 
 

 
 93)
 
P
 
 value
Demographics
Gender—male 98.9% 96.8% .31
Gender—female 1.1% 3.2% .31
Age (mean) 69.5 (SE 
 

 
 0.85) 70.1 (SE 
 

 
 0.86) .65
Race—White 59.1% 50.5% .15
Race—Black 35.5% 45.2% .12
Race—other 5.4% 4.3% .50
Married 34.4% 36.6% .44
Single/wid./div. 65.6% 63.4% .44
Medications (mean)
Number of COPD medications 3.28 (SE  0.06) 2.66 (SE  0.9) .0001
Number of nonCOPD medications 12.22 (SE  0.64) 8.66 (SE  0.51) .0001
Hospitalization and noncompliance (mean)
Number of total hospitalizations 2.54 (SE  0.20) 0.66 (SE  0.15) .0001
LOS of total hospitalizations (days) 20.03 (SE  2.18) 3.68 (SE  0.99) .0001
Number of COPD hospitalizations 1.55 N/A N/A
LOS of COPD hospitalizations (days) 10.5 N/A N/A
Number of nonCOPD hospitalizations 0.99 (SE  0.16) 0.66 (SE  0.15) .02
LOS of nonCOPD hospitalizations (days) 9.53 (SE  1.78) 3.68 (SE  0.99) .003
COPD medication noncompliance ratio 0.19 (SE  0.02) 0.20 (SE  0.02) .95
 
SE 
 

 
 standard error; LOS 
 

 
 length of stay; noncompliance ratio 
 

 
 total number of days without medications 
 

 
 total number of days medications prescribed.
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0.19 vs. 0.20). The difference, however, was not
statistically significant at the .05 level (
 
P
 
 
 

 
 .95).
Table 2 shows the distribution of patients by
degree of noncompliance at various cutpoints
ranging from 0.00 (100% compliance) to 
 

 
0.70
(30% compliance or less). A significant difference
between the two groups (
 
P
 
 
 

 
 .05) was noted only
in the 80–89% compliance range (noncompliance
ratio 0.2–
 

 
0.3). Patients were also classified into
three aggregate levels of noncompliance, high, me-
dium, or low, 
 

 
0.2, 0.2 to 
 

 
0.4, and 
 

 
0.4, re-
spectively, and the Chi square test was applied to
see if there was any difference between the cases
and controls at these levels. At a significance level
of .05 there was no difference between the two
groups at these three levels of noncompliance (
 
P
 
 
 

 
.44, 
 
P
 
 
 

 
 .15, 
 
P
 
 
 

 
 .22, respectively).
 
Discussion
 
A significant amount of healthcare resources are
being utilized to improve medication compliance
among patients with chronic conditions in the
hope of improving overall health status and at-
taining decreased levels of hospitalization. These
findings indicate that there was no difference in
medication noncompliance rates between patients
hospitalized for COPD and patients not hospital-
ized. In a VA population of elderly males, non-
compliance with medications may not be the sole
determinant of exacerbation of COPD and related
hospitalization. If the number of medications re-
quired to control COPD and the number of non-
COPD medications were treated as surrogate indi-
cators of severity of illness, one might infer that
the patients requiring admission are a generally
sicker group. They required significantly more
medications to control COPD and other comorbid
conditions and required more hospitalizations for
nonCOPD conditions.
One of the major limitations of this study was
that factors other than compliance, such as smok-
ing, compliance with oxygen therapy, environ-
mental and occupational pollution, and other co-
morbid conditions, were not included. These
factors may be important contributors to exacer-
bation of COPD. The study also assumes that a
prescription filled implies that the patient con-
sumed the medication as directed. Three of the
medications involved in the study were inhalers
that require a specific technique to derive maxi-
mum benefit from therapy. The study did not,
however, evaluate whether the patients were using
the inhalers appropriately.
Another limitation was that the noncompliance
ratio was calculated for a fixed period of 1 year
without taking into consideration whether the pa-
tient was admitted at the start or end of the study
period. Although all patients were counseled by
pharmacists on the use of their medications at the
time of prescription dispensing, they were likely to
receive more intensive counseling at the time of
any hospital discharge. It is possible that patients
who were hospitalized early in the study period re-
ceived such counseling and improved compliance.
Calculating the rate for a 1-year period immedi-
ately preceding hospitalization might yield a more
unbiased estimate of medication noncompliance
behavior prior to hospital admission. Moreover,
since the study was done on a VA population of
almost exclusively elderly males, it may not be
generalizable to other population groups. A longer
patient follow-up and a larger sample size would
also have improved the study’s design.
 
Table 2
 
Noncompliance data for patients hospitalized for exacerbation of COPD (cases) and not 
hospitalized COPD patients (controls)
 
Noncompliance Ratio Cases (
 
n
 
 
 

 
 93) Number (%) Controls (
 
n
 
 
 

 
 93) Number (%)
 
P
 
 value
0.0 11 (11.8) 18 (19.4) NS
0.01–
 

 
0.1 25 (26.9) 23 (24.7) NS
0.1–
 

 
0.2 19 (20.4) 16 (17.2) NS
0.2–
 

 
0.3 18 (19.4) 6 (6.5)
 

 
.05
0.3–
 

 
0.4 7 (7.5) 12 (12.9) NS
0.4–
 

 
0.5 8 (8.6) 6 (6.5) NS
0.5–
 

 
0.6 1 (1.1) 7 (7.5) NS
0.6–
 

 
0.7 3 (3.2) 4 (4.3) NS
0.7–1.0 1 (1.1) 1 (1.1) NS
 

 
0.2 55 (59.1) 57 (61.3) .44
0.2–
 

 
0.4 25 (26.9) 18 (19.4) .5
0.4 13 (14.0) 18 (19.4) .22
NS  nonsignificant; P  .05; noncompliance ratio  total number of days without medications  total number of days medica-
tions prescribed.
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In summary, medication noncompliance may
not be the most important determinant of hospi-
talization related to exacerbation of COPD. A
blind devotion to achieving 100% medication
compliance in this disease state may be unreason-
able and an ineffective use of clinical resources.
Other contributing causes need to be investigated.
The Department of Veterans Affairs has already
begun to identify patients who smoke, and target
such patients for smoking cessation programs at
each visit with the primary care provider.
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